Is RGEN a Buy? What to Consider in 2026

Last updated July 2026

Short answer

The bull case for Repligen Corporation (RGEN) rests on Bioprocessing recovery and organic reacceleration: After a multi-year destocking correction, Repligen returned to double-digit organic growth in early 2026 (11% organic in Q1) with broad-based strength across franchises and geographies. Revenue (TTM) is ~$708M. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Repligen trades at a rich valuation (around 8 times sales), so any stumble in organic growth or guidance can trigger sharp multiple compression. Whether RGEN is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.

Repligen Corporation makes consumable products and equipment used to manufacture biologic drugs, including monoclonal antibodies, gene therapies and vaccines. Its portfolio spans four franchises: filtration (KrosFlo and XCell ATF systems), chromatography resins and columns, proteins (notably Protein A ligands used to purify antibodies), and process analytics. Because roughly 80% of its offerings face limited direct competition and its consumables are embedded in customers' validated manufacturing processes, Repligen sells into a durable, recurring bioprocessing demand base rather than one-off equipment cycles. The investment picture is one of recovery from the post-pandemic bioprocessing destocking slump. In Q1 2026 revenue rose 15% as reported and 11% organic, with China sales doubling and analytics surging, prompting management to raise adjusted EPS guidance. Trailing-twelve-month revenue sits near $708 million and full-year 2026 guidance calls for roughly $810 million to $840 million. The debate for investors centers on valuation: at a market cap around $9.4 billion the stock trades near 8 times sales, so the shares price in a sustained return to double-digit growth.

What's the case for buying RGEN?

1. Bioprocessing recovery and organic reacceleration

After a multi-year destocking correction, Repligen returned to double-digit organic growth in early 2026 (11% organic in Q1) with broad-based strength across franchises and geographies. Recovering order patterns from biopharma customers and a doubling of China revenue signal that the inventory overhang has largely cleared. Sustained double-digit organic growth is the central pillar supporting the premium valuation.

2. New modalities and consumables mix

Gene therapy, cell therapy and mRNA manufacturing lean heavily on filtration and analytics, areas where Repligen holds differentiated technology. A growing share of consumables (resins, membranes, ligands) tied to installed equipment creates recurring, higher-margin revenue. As approved biologics scale into commercial production, per-batch consumable pull-through rises.

3. Margin expansion and disciplined M&A

Repligen delivered roughly 160 basis points of adjusted operating margin expansion in Q1 2026 and raised its adjusted EBITDA margin guidance toward the low-20s. The company has a history of bolt-on acquisitions (such as the 908 Devices analytics portfolio) that broaden its franchises, alongside pruning like the March 2026 Polymem divestiture. Improving profitability lifted the 2026 adjusted EPS outlook to roughly $1.97 to $2.05.

4. Secular biologics manufacturing demand

Long-term biologic and biosimilar volumes are expected to keep growing, and Repligen sits upstream as a supplier to nearly every major drug manufacturer and CDMO. This picks-and-shovels position means the company benefits from industry-wide production growth without exposure to any single drug's clinical outcome. That breadth underpins the durability of the demand base.

What are the risks to RGEN?

Repligen trades at a rich valuation (around 8 times sales), so any stumble in organic growth or guidance can trigger sharp multiple compression. The business is cyclical and sensitive to biopharma capital spending, funding conditions for smaller biotech customers, and inventory destocking, all of which hurt results in 2023 to 2024. Concentration among large pharma and CDMO customers, exposure to China and global tariff or trade policy, and integration risk from ongoing acquisitions add uncertainty. Competition from far larger rivals like Danaher's Cytiva and Sartorius could pressure pricing in overlapping product lines. Finally, as an equipment and consumables supplier, revenue can be lumpy quarter to quarter.

How is RGEN valued? (as of JULY 2026)

Price

$147.25

Market cap

$8.31B

P/E (TTM)

161.81

Forward P/E

57.72

Price / book

3.94

Beta

1.06

52-week range

$100.99 to $175.77

Snapshot for RGEN as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (TTM): ~$708M
FY2026 revenue guidance: ~$810M to $840M
Q1 2026 revenue growth: ~15% reported (11% organic)
FY2026 adjusted EPS guidance: ~$1.97 to $2.05
Market cap: ~$9.4B
Price/sales: ~8x

Repligen carries a premium valuation typical of high-quality life-science tools names, with a price-to-sales ratio near 8 despite mid-teens headline revenue growth. Management raised its 2026 profit outlook while roughly holding revenue guidance, reflecting a recovery that is more visible in margins than in top-line acceleration so far. The shares are widely viewed as fully priced on sales even if cash flow looks more reasonable.

How do you decide if RGEN is a buy?

Rather than asking whether RGEN is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold RGEN indirectly through an index or sector ETF before adding more.

For the full picture, see the RGEN stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about RGEN against your real portfolio and see your actual exposure before deciding.

The bottom line on RGEN

The bottom line: Repligen Corporation's story right now is Bioprocessing recovery and organic reacceleration, with revenue (ttm) at ~$708M. If you believe that narrative continues, the call is about sizing RGEN sensibly and checking overlap with what you own; if you doubt it (the risk: repligen trades at a rich valuation (around 8 times sales), so any stumble in organic growth or guidance can trigger sharp multiple compression.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.

Build a basket around RGEN with Walnut

Use Repligen Corporation as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.

Create a free Walnut account

FAQ

Is RGEN a good stock to buy right now?

The case for Repligen Corporation right now is Bioprocessing recovery and organic reacceleration, with revenue (ttm) at ~$708M. If you believe that thesis holds, RGEN is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is repligen trades at a rich valuation (around 8 times sales), so any stumble in organic growth or guidance can trigger sharp multiple compression. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.

What does Repligen Corporation do?

Repligen Corporation makes consumable products and equipment used to manufacture biologic drugs, including monoclonal antibodies, gene therapies and vaccines.

What are the main risks of RGEN?

What company is RGEN?

RGEN is the Nasdaq ticker for Repligen Corporation, a Massachusetts-based bioprocessing company that supplies filtration, chromatography, protein and process-analytics products used to manufacture biologic drugs like antibodies and gene therapies.

What does Repligen actually sell?

Repligen sells consumables and equipment across four franchises: filtration (KrosFlo and XCell ATF systems), chromatography resins and columns, proteins including Protein A ligands used to purify antibodies, and process analytics instruments. Its products are embedded in drugmakers' manufacturing lines.

Is Repligen profitable?

Yes. Repligen is profitable on both a GAAP and adjusted basis, and it guided full-year 2026 adjusted EPS to roughly $1.97 to $2.05 after raising its outlook. Q1 2026 GAAP EPS rose about 50% and adjusted EPS about 23% year over year.

How fast is Repligen growing?

In Q1 2026 revenue grew about 15% as reported and 11% organically as the bioprocessing market recovered from a destocking slump. Full-year 2026 organic growth guidance is roughly 9% to 13%, with total revenue guided to about $810 million to $840 million.

Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell RGEN; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.